The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV ...
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development ...
New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first readout targets 2027. SPVN06, a novel gene-agnostic adeno-associated virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results